{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T22:46:50Z","timestamp":1696978010783},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1053\/snep.2002.35963","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:35:46Z","timestamp":1478565346000},"page":"474-478","source":"Crossref","is-referenced-by-count":3,"title":["Anemia Treatment in Chronic Renal Insufficiency"],"prefix":"10.1053","volume":"22","author":[{"given":"Steven","family":"Fishbane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/snep.2002.35963_bib1","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1046\/j.1523-1755.2001.00002.x","article-title":"Trends in anemia at initiation of dialysis in the United States","volume":"60","author":"Obrador","year":"2001","journal-title":"Kidney Int"},{"key":"10.1053\/snep.2002.35963_bib2","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1681\/ASN.V1081793","article-title":"Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States","volume":"10","author":"Obrador","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/snep.2002.35963_bib3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0272-6386(96)90383-2","article-title":"Excess morbidity in patients starting uremia therapy without prior care by a nephrologist","volume":"28","author":"Ifudu","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/snep.2002.35963_bib4","first-page":"732","article-title":"Physiologic studies in normal and uremic sheep","volume":"18","author":"Eschbach","year":"1980","journal-title":"II. Changes in erythropoiesis and oxygen transport. Kidney Int"},{"key":"10.1053\/snep.2002.35963_bib5","first-page":"20","article-title":"The mechanism of erythropoietin action","volume":"18","author":"Koury","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/snep.2002.35963_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/jcp.1041560207","article-title":"Apoptosis of human erythroid colony- forming cells is decreased by stem cell factor and insulinlike growth factor I as well as erythropoietin","volume":"156","author":"Muta","year":"1993","journal-title":"J Cell Physiol"},{"key":"10.1053\/snep.2002.35963_bib7","first-page":"434","article-title":"The anemia of chronic renal failure in sheep","volume":"74","author":"Eschbach","year":"1984","journal-title":"Response to erythropoietinrich plasma in vivo. J Clin Invest"},{"key":"10.1053\/snep.2002.35963_bib8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/313806a0","article-title":"Isolation and characterization of genomic and cDNA clones of human erythropoietin","volume":"313","author":"Jacobs","year":"1985","journal-title":"Nature"},{"key":"10.1053\/snep.2002.35963_bib9","first-page":"73","article-title":"Correction of the anemia of end-stage renal disease with recombinant human erythropoietin","volume":"316","author":"Eschbach","year":"1987","journal-title":"Results of a combined phase I and II clinical trial, N Engl J Med"},{"key":"10.1053\/snep.2002.35963_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/ajkd.2001.27699","article-title":"Anemia: An early complication of chronic renal insufficiency","volume":"38","author":"Kazmi","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/snep.2002.35963_bib11","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1046\/j.1523-1755.2001.00077.x","article-title":"A randomized trial of iron deficiency testing strategies in hemodialysis patients","volume":"60","author":"Fishbane","year":"2001","journal-title":"Kidney Int"},{"key":"10.1053\/snep.2002.35963_bib12","first-page":"108","article-title":"Recombinant human erythropoietin treatment in pre-dialysis patients","volume":"110","author":"Lim","year":"1989","journal-title":"A double- blind placebo-controlled trial. Ann Intern Med"},{"key":"10.1053\/snep.2002.35963_bib13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0272-6386(89)80149-0","article-title":"The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-controlled trial","volume":"14","author":"Kleinman","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/snep.2002.35963_bib14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0272-6386(95)90122-1","article-title":"Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients","volume":"25","author":"Revicki","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/snep.2002.35963_bib15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0272-6386(89)80148-9","article-title":"Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients","volume":"14","author":"Wolcott","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/snep.2002.35963_bib16","first-page":"14","article-title":"Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients","volume":"14","author":"Delano","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/snep.2002.35963_bib17","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1067\/mhj.2000.111112","article-title":"Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension","volume":"140","author":"Brown","year":"2000","journal-title":"Am Heart J"},{"key":"10.1053\/snep.2002.35963_bib18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0002-9629(15)40499-9","article-title":"Why is left ventricular hypertrophy so predictive of morbidity and mortality?","volume":"317","author":"Benjamin","year":"1999","journal-title":"Am J Med Sci"},{"issue":"suppl 3","key":"10.1053\/snep.2002.35963_bib19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/BF00877223","article-title":"Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality","volume":"8","author":"Kaplinsky","year":"1994","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1053\/snep.2002.35963_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000175819","article-title":"Left ventricular hypertrophy and mortality-results from the Framingham Study","volume":"81","author":"Kannel","year":"1992","journal-title":"Cardiology"},{"key":"10.1053\/snep.2002.35963_bib21","first-page":"146","article-title":"Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems","volume":"39","author":"Rocco","year":"2002","journal-title":"The National Institutes of Health-Funded Hemodialysis. Health Care Financing Administration. Am J Kidney Dis"},{"key":"10.1053\/snep.2002.35963_bib22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ki.1995.22","article-title":"Clinical and echocardiographic disease in patients starting end-stage renal disease therapy","volume":"47","author":"Foley","year":"1995","journal-title":"Kidney Int"},{"key":"10.1053\/snep.2002.35963_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0272-6386(96)90357-1","article-title":"Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention","volume":"27","author":"Levin","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/snep.2002.35963_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0272-6386(99)70118-6","article-title":"Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin","volume":"34","author":"Levin","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/snep.2002.35963_bib25","first-page":"561","article-title":"Erythropoietin and arterial hypertension","volume":"53","author":"Luft","year":"2000","journal-title":"Clin Nephrol"},{"key":"10.1053\/snep.2002.35963_bib26","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0272-6386(99)70413-0","article-title":"Mechanism of erythropoietin-induced hypertension","volume":"33","author":"Vaziri","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/snep.2002.35963_bib27","first-page":"81","article-title":"Erythropoietin and hypertension","volume":"9","author":"Nowicki","year":"1995","journal-title":"J Hum Hypertens"},{"key":"10.1053\/snep.2002.35963_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000188699","article-title":"Arterial hypertension in uraemic patients treated with erythropoietin","volume":"71","author":"Kokot","year":"1995","journal-title":"Nephron"},{"key":"10.1053\/snep.2002.35963_bib29","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1073\/pnas.85.16.6142","article-title":"Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass","volume":"85","author":"Garcia","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/snep.2002.35963_bib30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0272-6386(12)80671-8","article-title":"Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients","volume":"24","author":"Roth","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/snep.2002.35963_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ki.1990.18","article-title":"Effect of recombinant human erythropoietin on renal function in humans","volume":"37","author":"Lim","year":"1990","journal-title":"Kidney Int"},{"key":"10.1053\/snep.2002.35963_bib32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000168067","article-title":"Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients","volume":"10","author":"Abraham","year":"1990","journal-title":"Am J Nephrol"},{"key":"10.1053\/snep.2002.35963_bib33","first-page":"782","article-title":"Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients","volume":"4","author":"Frenken","year":"1989","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/snep.2002.35963_bib34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ndt\/16.2.307","article-title":"Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients","volume":"16","author":"Jungers","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/snep.2002.35963_bib35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000190270","article-title":"Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients","volume":"77","author":"Kuriyama","year":"1997","journal-title":"Nephron"},{"key":"10.1053\/snep.2002.35963_bib36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/003655999750015989","article-title":"Subcutaneous treatment with recombinant human erythropoietin-the influence of injection frequency and skin-fold thickness","volume":"33","author":"Brahm","year":"1999","journal-title":"Scand J Urol Nephrol"},{"issue":"suppl 1","key":"10.1053\/snep.2002.35963_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/bjoc.2001.1746","article-title":"Development and characterization of novel erythropoiesis stimulating protein (NESP)","volume":"84","author":"Egrie","year":"2001","journal-title":"Br J Cancer"},{"issue":"suppl 3","key":"10.1053\/snep.2002.35963_bib38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ndt\/16.suppl_3.14","article-title":"An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP)","volume":"16","author":"Macdougall","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/snep.2002.35963_bib39","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.2165\/00003495-200161140-00010","article-title":"Darbepoetin alfa: A viewpoint by lain C","volume":"61","author":"Macdougall","year":"2001","journal-title":"Macdougall. Drugs"},{"key":"10.1053\/snep.2002.35963_bib40","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/14712598.1.4.733","article-title":"The clinical potential of novel erythropoiesis stimulating protein","volume":"1","author":"Sunder-Plassmann","year":"2001","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/snep.2002.35963_bib41","first-page":"320","article-title":"Current concepts of anemia management in chronic renal failure: Impact of NKF-DOQI","volume":"20","author":"Eschbach","year":"2000","journal-title":"Semin Nephrol"},{"key":"10.1053\/snep.2002.35963_bib42","first-page":"104","article-title":"Family practice residents' awareness of medical care costs in British Columbia","volume":"34","author":"Allan","year":"2002","journal-title":"Fam Med"},{"key":"10.1053\/snep.2002.35963_bib43","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ajhp\/57.22.2041","article-title":"Physicians care about drug costs but lack information","volume":"57","author":"Kepple","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"10.1053\/snep.2002.35963_bib44","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1532-5415.1994.tb06594.x","article-title":"Physicians' knowledge of drug costs for the elderly","volume":"42","author":"Glickman","year":"1994","journal-title":"J Am Geriatr Soc"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929502700478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929502700478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T06:49:23Z","timestamp":1635662963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929502700478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["S0270929502700478"],"URL":"https:\/\/doi.org\/10.1053\/snep.2002.35963","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2002,11]]}}}